Publication at First Faculty of Medicine |
2019
Abstract
Melanoma belongs to significantly immunogenic tumors, allowing for immunological approaches. Melanoma immunotherapy is possibly used in adjuvant administration as well as in metastatic disease.
Interferon alpha is used for adjuvant treatment without a significant effect in long-term follow-up. More recently, checkpoint inhibitors (anti-CTLA4, PD1/PD-L1) are used in clinical trials also for adjuvant treatment, which are already standard in metastatic disease.
The work discusses the most recent clinical trials and points to the possibilities of combined therapy with targeted therapy. New approaches and future directions for immunotherapy of melanoma are also discussed.